Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc., based in Cranford, New Jersey, is a biopharmaceutical company focused on developing and commercializing critical care products, particularly in oncology, anti-infectives for adjunct cancer care, and unique prescription products. The company aims for leading market positions by offering therapeutic products that address unmet medical needs with lower development risk, often by reformulating previously approved drugs with existing safety and efficacy data. This strategy focuses on products with intellectual property and regulatory exclusivity. In December 2025, Citius Pharmaceuticals became a commercial company with the launch of LYMPHIR by its majority-owned subsidiary, Citius Oncology. LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, received FDA approval for treating patients with persistent or recurrent cutaneous T-cell lymphoma ("CTCL"). Citius Pharma in-licensed LYMPHIR in September 2021, and it is now owned by Citius Oncology. The company is also developing three proprietary products: Mino-Lok, an antibiotic lock solution for catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation for hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for ARDS. Since its inception, the company has focused on business planning, acquiring technology, research and development, staffing, and raising capital.